EP
FHTX icon

Essential Partners’s Foghorn Therapeutics FHTX Stock Holding History

Essential Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171 Sell
35
-77
-69% -$342 ﹤0.01% 2667
2026
Q1 		$535 Buy
+112
New +$615 ﹤0.01% 2418
2025
Q4 		– Sell
-5
Closed -$24 – 2819
2025
Q3 		$24 Hold
5
– – ﹤0.01% 2624
2025
Q2 		$24 Buy
+5
New +$21 ﹤0.01% 2212

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Essential Partners's FHTX Position: Q2 2026 in Review

Essential Partners reduced its Foghorn Therapeutics (FHTX) stake by 69% in Q2 2026, selling an estimated $342 and leaving 35 shares worth $171. The position accounts for ﹤0.01% of the portfolio, ranked #2667.

Essential Partners first reported a position in FHTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $535 in Q1 2026. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Essential Partners held 35 shares of Foghorn Therapeutics worth $171 as of Q2 2026.
  • Essential Partners sold 77 Foghorn Therapeutics shares in Q2 2026, an estimated $342.
  • Foghorn Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2667 holding.
  • Essential Partners first reported a position in Foghorn Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Essential Partners's Foghorn Therapeutics position peaked at $535 in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.